Anticorps Polyclonal de lapin anti-PSMD9

• Phare
• Validé par KD/KO

PSMD9 Polyclonal Antibody for WB, IHC, IF/ICC, FC (Intra), IP, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, souris

Applications

WB, IHC, IF/ICC, FC (Intra), IP, ELISA

Conjugaison

Non conjugué

N° de cat : 26922-1-AP

Synonymes

26S proteasome non-ATPase regulatory subunit 9, p27, Rpn4

---

Galerie de données de validation

• 

  WB analysis of A549 using 26922-1-AP

  A549 cells were subjected to SDS PAGE followed by western blot with 26922-1-AP (PSMD9 Antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of A549 using 26922-1-AP

  WB result of PSMD9 antibody (26922-1-AP; 1:1000; incubated at room temperature for 1.5 hours) with sh-Control and sh-PSMD9 transfected A549 cells.

• 

  WB analysis of mouse spleen using 26922-1-AP

  mouse spleen tissue were subjected to SDS PAGE followed by western blot with 26922-1-AP (PSMD9 antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of Jurkat using 26922-1-AP

  Jurkat cells were subjected to SDS PAGE followed by western blot with 26922-1-AP (PSMD9 antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of A549 using 26922-1-AP

  A549 cells were subjected to SDS PAGE followed by western blot with 26922-1-AP (PSMD9 antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of MCF-7 using 26922-1-AP

  MCF-7 cells were subjected to SDS PAGE followed by western blot with 26922-1-AP (PSMD9 antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of MDA-MB-453s using 26922-1-AP

  MDA-MB-453s cells were subjected to SDS PAGE followed by western blot with 26922-1-AP (PSMD9 antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HepG2 using 26922-1-AP

  HepG2 cells were subjected to SDS PAGE followed by western blot with 26922-1-AP (PSMD9 antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

• 

  IP experiment of A549 using 26922-1-AP

  IP result of anti-PSMD9 (IP:26922-1-AP, 4ug; Detection:26922-1-AP 1:400) with A549 cells lysate 1330 ug.

• 

  IHC staining of human breast cancer using 26922-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 26922-1-AP (PSMD9 Antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human breast cancer using 26922-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 26922-1-AP (PSMD9 Antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IF Staining of U2OS using 26922-1-AP

  Immunofluorescent analysis of (-20°C Methanol) fixed U2OS cells using PSMD9 antibody (26922-1-AP) at dilution of 1:200 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) (SA00013-2).

• 

  IF Staining of A549 using 26922-1-AP

  Immunofluorescent analysis of (-20°C Methanol) fixed A549 cells using PSMD9 antibody (26922-1-AP) at dilution of 1:400 and Multi-rAb CoraLite ® Plus 488-Goat Anti-Rabbit Recombinant Secondary Antibody (H+L) (RGAR002).

• 

  FC experiment of HeLa using 26922-1-AP

  1x10^6 HeLa cells were intracellularly stained with 0.8 ug Anti-Human PSMD9 (26922-1-AP)(red), or 0.8 ug rabbit IgG isotype control (blue). Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).

---

Applications testées

• Résultats positifs en WB: cellules A549, cellules HepG2, cellules Jurkat, cellules MCF-7, cellules MDA-MB-453s, tissu splénique de souris
• Résultats positifs en IP: cellules A549,
• Résultats positifs en IHC: tissu de cancer du sein humain; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.
• Résultats positifs en IF/ICC: cellules U2OS, cellules A549
• Résultats positifs en FC (Intra): cellules HeLa,

Dilution recommandée

• Western Blot (WB): WB : 1:1000-1:6000
• Immunoprécipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunohistochimie (IHC): IHC : 1:50-1:500
• Immunofluorescence (IF)/ICC: IF/ICC : 1:50-1:500
• Flow Cytometry (FC) (INTRA): FC (INTRA) : 0.80 ug per 10^6 cells in a 100 µl suspension

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Informations sur le produit

26922-1-AP cible PSMD9 dans les applications de WB, IHC, IF/ICC, FC (Intra), IP, ELISA et montre une réactivité avec des échantillons Humain, souris

• Réactivité: Humain, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: PSMD9 Protéine recombinante Ag25638
• Nom complet: proteasome (prosome, macropain) 26S subunit, non-ATPase, 9
• Masse moléculaire calculée: 27 kDa
• Poids moléculaire observé: 25-30 kDa
• Numéro d’acquisition GenBank: BC004213
• Symbole du gène: PSMD9
• Identification du gène (NCBI): 5715
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

PSMD9 is a ubiquitous protein of eukaryotic cells and is a chaperon of the 26S proteasome complex, which degrades ubiquitinated proteins in eukaryotic cells and contributes to the degradation of intracellular proteins into antigenic peptides for antigen presentation by MHC class I cells. The 26S mammalian base sub-complex involves three distinct modules which have ATPase subunits distinctly associated to three chaperones, one of which is PSMD9 regulating the modules assembly. The PSMD9 ubiquitous regulatory role within the proteasome implies its potential pleiotropic effects within different physio-pathological systems. PSMD9 is known to form a stable subcomplex with PSMC3 and PSMC6, two of the AAA-ATPases, assisting in the assembly of the 20S and 19S particles to form the holo complex.

{{ptg:RelatedPrimaryAntibodies}}